CRISPR/VERTEX get UK conditional approval for CASGEVY in sickle cell & beta thalassemia

CRISPR Therapeutics AG

CASGEVY (exagamglogene autotemcel) received conditional marketing authorization from UK MHRA.
Approved for patients 12+ with sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.
Authorization requires no human leukocyte antigen matched related donor; valid for one year, renewable annually.
CRISPR and partner Vertex jointly developed the CRISPR/Cas9 gene-edited therapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.